Faculty
Steven R. Levine, MD, FAHA, FAAN, FANA
Professor of Neurology & Emergency Medicine
Executive Vice Chair, Neurology
Chief of Neurology, University Hospital of Brooklyn
Associate Dean for Clinical Research & Faculty Development
The State University of New York (SUNY) Health Science Center - Brooklyn
Downstate Medical Center & Stroke Center
Brooklyn, New York
Stanley Tuhrim, M.D.
Professor and Vice Chair of Clinical Affairs
Department of Neurology
Icahn School of Medicine at Mount Sinai
Director, Mount Sinai Stroke Center
New York, N.Y.
Matthew E. Fink, M.D. FAAN, FAHA, FANA
Chairman, Neurology
Associate Dean for Clinical Affairs
Weill Cornell Medicine / New York Presbyterian
"Mobile Stroke Treatment Units - Now and into the Future"
Christopher Kellner, M.D.
Assistant Professor of Neurosurgery
Icahn School of Medicine at Mount Sinai
Robert Phillips, M.D., Ph.D
EVP and Chief Medical Officer, Houston Methodist; President and CEO Houston Methodist Physician Organization, Houston, TX
Professor of Medicine, Weill Cornell Medical College, New York
Ethan S. Brandler, M.D., MPH, FACEP
Associate Director of Emergency Medical Services
Assistant Professor of Clinical Emergency Medicine
SUNY Stony Brook
Stony Brook, New York
Evan Stein, M.D, Ph.D.
Assistant Professor of Radiology
Albert Einstein College of Medicine
Joanna T. Fifi, M.D.
Associate Professor of Neurosurgery, Neurology, and Radiology
Icahn School of Medicine at Mount Sinai, New York
David Vorchheimer, M.D.
Cardiology
Montefiore Medical Center
Faculty Disclosure
It is the policy of Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculties participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices.
Professor of Neurology & Emergency Medicine
Executive Vice Chair, Neurology
Chief of Neurology, University Hospital of Brooklyn
Associate Dean for Clinical Research & Faculty Development
The State University of New York (SUNY) Health Science Center - Brooklyn
Downstate Medical Center & Stroke Center
Brooklyn, New York
Stanley Tuhrim, M.D.
Professor and Vice Chair of Clinical Affairs
Department of Neurology
Icahn School of Medicine at Mount Sinai
Director, Mount Sinai Stroke Center
New York, N.Y.
Matthew E. Fink, M.D. FAAN, FAHA, FANA
Chairman, Neurology
Associate Dean for Clinical Affairs
Weill Cornell Medicine / New York Presbyterian
"Mobile Stroke Treatment Units - Now and into the Future"
Christopher Kellner, M.D.
Assistant Professor of Neurosurgery
Icahn School of Medicine at Mount Sinai
Robert Phillips, M.D., Ph.D
EVP and Chief Medical Officer, Houston Methodist; President and CEO Houston Methodist Physician Organization, Houston, TX
Professor of Medicine, Weill Cornell Medical College, New York
Ethan S. Brandler, M.D., MPH, FACEP
Associate Director of Emergency Medical Services
Assistant Professor of Clinical Emergency Medicine
SUNY Stony Brook
Stony Brook, New York
Evan Stein, M.D, Ph.D.
Assistant Professor of Radiology
Albert Einstein College of Medicine
Joanna T. Fifi, M.D.
Associate Professor of Neurosurgery, Neurology, and Radiology
Icahn School of Medicine at Mount Sinai, New York
David Vorchheimer, M.D.
Cardiology
Montefiore Medical Center
Faculty Disclosure
It is the policy of Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculties participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices.